Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model

Francesco Alessandrini(University of Genoa), Paolo Malatesta(Ospedale Policlinico San Martino), Gabriella Campadelli‐Fiume(University of Bologna), Laura Menotti(University of Bologna), Irene Appolloni(University of Genoa), Davide Ceresa(University of Genoa), Elisa Avitabile(University of Bologna), Daniela Marubbi(Ospedale Policlinico San Martino)

Oncogene

February 12, 2019

10.1038/s41388-019-0737-2

Cited by 78

Related Papers

Entry of herpes simplex virus 1 in BJ cells that constitutively express viral glycoprotein D is by endocytosis and results in degradation of the virus

|Journal of Virology|1988|201

Dissecting the effects of preconditioning with inflammatory cytokines and hypoxia on the angiogenic potential of mesenchymal stromal cell (MSC)-derived soluble proteins and extracellular vesicles (EVs)

|Biomaterials|2020|136

Herpes simplex virus glycoprotein D is sufficient to induce spontaneous pH-independent fusion in a cell line that constitutively expresses the glycoprotein

|Virology|1988|53

Construction and properties of a cell line constitutively expressing the herpes simplex virus glycoprotein B dependent on functional alpha 4 protein synthesis

|Journal of Virology|1986|38

Early clonal extinction in glioblastoma progression revealed by genetic barcoding

|Cancer Cell|2023|32